Skip to content
Triangle logo TriangleGet started
← Study library

NCT00981058 · CITED IN SOURCE DOCUMENTS

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2025-06-18

The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival Time (OS)

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])

→

outcome · POSTED

Time to Treatment Failure (TTF)

→

outcome · POSTED

Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)

→

outcome · POSTED

Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)

→

outcome · POSTED

Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)

→

outcome · POSTED

Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab

→

outcome · POSTED

Number of Participants With a Serum Anti-Necitumumab Antibody Assessment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Has histologically or cytologically confirmed squamous NSCLC * Has Stage IV disease at the time of study entry * Measurable or nonmeasurable disease at the time of study entry as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) (participants with only truly nonmeasurable disease are not eligible) * Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia) * Has adequate hepatic function * Has adequate renal function * Has adequate hematologic function * If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method (failure rate \< 1%) during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) * If male, the participant is surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period * Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization * Has archived tumor tissue available for analysis of EGFR and KRAS mutation status (by PCR) and EGFR gene copy number (by FISH); minimum of four slides, paraffin-embedded tissue, required Exclusion Criteria: * Has nonsquamous NSCLC (adenocarcinoma/large cell or other) * Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor * Has received previous chemotherapy for advanced NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization) * Has undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization * Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed) * Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible * Has superior vena cava syndrome contraindicating hydration * Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure * Has experienced myocardial infarction within 6 months prior to randomization * Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus * Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder * Has any National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0 Grade ≥ 2 peripheral neuropathy * Has significant third space fluid retention, requiring repeated drainage * Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the participant's ability to complete the study or sign an informed consent document * Has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab (IMC-11F8), or any other contraindication to one of the administered treatments * Is pregnant or breastfeeding * Has a known history of drug abuse * Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Necitumumab: 800 milligrams (mg) I.V. infusion on Days 1 and 8 of every 3 week cycle. Continues until progressive disease, toxicity, noncompliance, or withdrawal. Gemcitabine: 1250 milligrams/square meter (mg/m2) on Days 1 and 8 of every 3 week cycle. Continues for a maximum of six cycles. Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle. Continues for a maximum of six cycles.
    intervention Names
    1. Biological: Necitumumab
    2. Drug: Gemcitabine
    3. Drug: Cisplatin
    label
    Necitumumab + Gemcitabine + Cisplatin
    type
    EXPERIMENTAL
  2. description
    Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle. Continues for a maximum of six cycles. Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle. Continues for a maximum of six cycles.
    intervention Names
    1. Drug: Gemcitabine
    2. Drug: Cisplatin
    label
    Gemcitabine + Cisplatin
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Necitumumab + Gemcitabine + Cisplatin
    description
    Administered intravenously. Continues until progressive disease, toxicity, noncompliance, or withdrawal.
    name
    Necitumumab
    other Names
    1. IMC-11F8
    2. LY3012211
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Gemcitabine + Cisplatin
    2. Necitumumab + Gemcitabine + Cisplatin
    description
    Administered intravenously. Continues for a maximum of six cycles.
    name
    Gemcitabine
    other Names
    1. LY2334737
    type
    DRUG
  3. arm Group Labels
    1. Gemcitabine + Cisplatin
    2. Necitumumab + Gemcitabine + Cisplatin
    description
    Administered intravenously. Continues for a maximum of six cycles.
    name
    Cisplatin
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
1093
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method.
    measure
    Overall Survival Time (OS)
    time Frame
    Randomization to Death from Any Cause (Up to 31 Months)
secondary Outcomes
  1. description
    PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Participants who die without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.
    measure
    Progression-Free Survival (PFS)
    time Frame
    Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)
  2. description
    ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions. PR defined as a \>=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) \* 100.
    measure
    Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])
    time Frame
    Baseline to Measured Progressive Disease (Up to 31 Months)
  3. description
    TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study.
    measure
    Time to Treatment Failure (TTF)
    time Frame
    Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)
  4. description
    The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
    measure
    Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)
    time Frame
    Baseline, Cycle 6 (Cycle = 3 Weeks)
  5. description
    The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.
    measure
    Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)
    time Frame
    Baseline, Cycle 6 (Cycle = 3 Weeks)
  6. description
    EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of \<200 and participants with a high EGFR expression defined by a H-score of cutoff value of \>=200.
    measure
    Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)
    time Frame
    31 Months
  7. measure
    Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab
    time Frame
    Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months
  8. description
    A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point.
    measure
    Number of Participants With a Serum Anti-Necitumumab Antibody Assessment
    time Frame
    Baseline through 31 Months
Full study description
brief Summary
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
detailed Description
Multinational, randomized, multicenter, open-label, Phase III study of 1093 participants (age ≥ 18 years) with histologically- or cytologically-confirmed, stage IV squamous-cell NSCLC, who have received no prior therapy for metastatic disease, will be randomized on a 1:1 basis to receive first-line necitumumab plus chemotherapy consisting of gemcitabine and cisplatin in study Arm A, or gemcitabine-cisplatin chemotherapy alone in study Arm B. Baseline radiographic assessment of disease will be performed within 21 days prior to randomization (first treatment will be administered within 7 days following randomization). Participants will undergo radiographic assessment of disease status (computed tomography or magnetic resonance imaging) every 6 weeks (± 3 days), until there is radiographic documentation of progressive disease (PD). Chemotherapy will continue for a maximum of six cycles in each arm (or until there is radiographic documentation of PD, toxicity requiring cessation, protocol noncompliance or withdrawal of consent); participants in Arm A only will continue to receive necitumumab until there is radiographic documentation of PD, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent. After the end-of-study-visit (following PD), follow-up information regarding further anticancer treatment and survival will be collected every 2 months (± 7 days). For participants who discontinue study for reasons other than PD (eg, symptomatic deterioration), information on disease progression will also be collected until PD is documented. Follow-up will continue as long as the participant is alive, or until the end of the trial.
Source references
references
  1. citation
    Yuan M, Su S, Ding H, Yang Y, Gupta M, Xu XS. Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning models. BMC Med Inform Decis Mak. 2026 Jun 30. doi: 10.1186/s12911-026-03671-2. Online ahead of print.
    pmid
    42381014
    type
    DERIVED
  2. citation
    Ciuleanu T, Socinski MA, Obasaju C, Luft AV, Szczesna A, Szafranski W, Ramlau R, Balint B, Molinier O, Depenbrock H, Nanda S, Paz-Ares L, Thatcher N. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Mar;19(2):130-138.e2. doi: 10.1016/j.cllc.2017.10.004. Epub 2017 Oct 13.
    pmid
    29158123
    type
    DERIVED
  3. citation
    Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9. doi: 10.1093/annonc/mdw214. Epub 2016 May 20.
    pmid
    27207107
    type
    DERIVED
  4. citation
    Reck M, Socinski MA, Luft A, Szczesna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016 Jun;11(6):808-18. doi: 10.1016/j.jtho.2016.03.002. Epub 2016 Mar 12.
    pmid
    26980471
    type
    DERIVED
  5. citation
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Balint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
    pmid
    26045340
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-906a137b2211867be226
      requested nct id
      NCT00981058
      primary nct id
      NCT00981058
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      payload sha256
      9380876e6f350f2291b5034d5a75b172caa8cc0850057866f3033e51a3f4e5a9
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-906a137b2211867be226
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00981058
      occurrences
      1. context exact
        t/section_11.39">39</a>,<a href="#cit/section_11.40">40</a>]<div class="pdq-content-list"><ol id="_484887" class="lower-alpha"><li>The <a href="/clinicaltrials/NCT00981058">SQUIRE</a> trial (NCT00981058) randomly assigned 1,093 patients with advanced squamous NSCLC to receive either first-line chemotherapy with cisplatin and gem
        end
        470206
        exact text
        NCT00981058
        start
        470195
      2. context exact
        ="#cit/section_11.40">40</a>]<div class="pdq-content-list"><ol id="_484887" class="lower-alpha"><li>The <a href="/clinicaltrials/NCT00981058">SQUIRE</a> trial (NCT00981058) randomly assigned 1,093 patients with advanced squamous NSCLC to receive either first-line chemotherapy with cisplatin and gemcitabine or the same regimen w
        end
        470237
        exact text
        NCT00981058
        start
        470226
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
      source file sha256
      6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:59.782436+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
      source title
      Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 15, 2025
        datetime
        2025-05-15T12:00:00Z
        display
        May 15, 2025

    Preserved source evidence · Not medical advice